Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome

NCT00486876 is registered in ClinicalTrials.gov with Pharmos as lead sponsor.

NCT NCT00486876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00486876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome
Lead sponsor
Pharmos
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
October 31, 2009
Enrollment
324 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome